Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 1997

View Archived Issues

Orally active HNE inhibitors from Cortech effective in lung injury model

Pharmacological profile of selective, orally active PDE IV inhibitor

Mechanism of antiasthmatic action of inhaled furosemide investigated

CytRx and Zynaxis complete merger

Cortex to evaluate CX-516 for the treatment of schizophrenia

Texas Biotechnology reports phase III results with Novastan in HIT and HITTS

Celtrix receives additional U.S. patents

Clinical efficacy and safety of Accolate for asthma

Dusa reports progress in phase III trial of Levulan PDT

RPR and Stanford enter research agreement for drug discovery and gene therapy

Scriptgen and Lilly enter drug discovery collaboration

Antiretroviral therapy and hearing loss

Schwarz Pharma and LocalMed work together on antirestenosis drug

Fluconazole safe and effective for tinea corporis/cruris

NeoPharm reports on antisense liposomes which inhibit Raf-1 proteins

OPC-14117 effective in mouse model of motor neuron disease

AmBisome cleared for marketing in Brazil

Novavax to initiate dose-ranging trial of Helicore

Mylan receives FDA approval of generic captopril/hydrochlorothiazide

Update on PDT's Purlytin

Dusa enters collaboration for Levulan PD of bladder cancer

Improved microtubule-inhibitory anticancer agents in development

FUB-181: Potent and selective H3 antagonist

Promising phase II results for thalidomide in brain cancer and Kaposi's sarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...